Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for IDH1- and IDH2-mutated acute myeloid leukaemia, drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Ivosidenib-azacitidine or venetoclax-azacitidine first, or all three together.
Managing differentiation syndrome without stopping an effective drug.
Isoform switching and second-site mutations that escape a single IDH inhibitor.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
Newly diagnosed IDH1-mutated AML with azacitidine (AGILE)
Relapsed/refractory IDH1-mutated AML
OS 24.
A milestone in how this cancer is treated.
OS 14.